[ad_1]
For the second time, the US Food and Drug Administration (FDA) approved the drug Vitrakvi at the end of November, which mainly targets genetic mutations of cancerous tumors. This drug has been shown to be effective in young adults and teens with solid tumors called NTRK, responsible for cancer growth.
According to the American Cancer Society, this type of genetic mutation is not common, but occurs in thyroid cancers, salivary glands, lungs and some types of sarcomas. This medicine is used to treat common or non-septic tumors that have developed in previous treatments.
This approval of the drug is an important step in the development of treatments that treat genetic mutations of tumors regardless of the location of their origin in the human body.
The US Food and Drug Administration approved and approved the drug after conducting 3 clinical trials involving 55 adolescents and children with solid NTRK tumors. Tumors in these patients can not be removed surgically or worsened after treatment.
All patients received VITRAKFI tablets: approximately 73% responded and showed improvement for 6 months, while 39% did not respond within one year.
VITRAKAFI has received a quick approval that allows the US Food and Drug Administration to approve drugs for severe cases and to address medical needs based on clinical data and clinical trials that serve and assist patients.
[ad_2]
Source link
